Literature DB >> 23038652

Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition?

Julia Wattacheril1, Naga Chalasani.   

Abstract

Entities:  

Year:  2012        PMID： 23038652      PMCID： PMC3511819          DOI： 10.1002/hep.26031

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  9 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

3.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

Authors:  Michael R Charlton; Justin M Burns; Rachel A Pedersen; Kymberly D Watt; Julie K Heimbach; Ross A Dierkhising
Journal:  Gastroenterology       Date:  2011-07-02       Impact factor: 22.682

4.  Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.

Authors:  Maria Stepanova; Zobair M Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-13       Impact factor: 11.382

5.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

6.  Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

Authors:  Janus P Ong; Angela Pitts; Zobair M Younossi
Journal:  J Hepatol       Date:  2008-07-09       Impact factor: 25.083

7.  Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

Authors:  Winston Dunn; Ronghui Xu; Deborah L Wingard; Christopher Rogers; Paul Angulo; Zobair M Younossi; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

8.  Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Gastroenterology       Date:  2008-10-29       Impact factor: 22.682

9.  Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study.

Authors:  Mariana Lazo; Ruben Hernaez; Susanne Bonekamp; Ihab R Kamel; Frederick L Brancati; Eliseo Guallar; Jeanne M Clark
Journal:  BMJ       Date:  2011-11-18
  9 in total
  15 in total

1.  Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Zhigang Duan; Xiaoying Yu; Donna White; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

Review 2.  Preclinical models of non-alcoholic fatty liver disease.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Arun J Sanyal
Journal:  J Hepatol       Date:  2017-11-09       Impact factor: 25.083

3.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

Authors:  Jennifer E Lambert; Maria A Ramos-Roman; Jeffrey D Browning; Elizabeth J Parks
Journal:  Gastroenterology       Date:  2013-12-04       Impact factor: 22.682

Review 4.  Metformin and metabolic diseases: a focus on hepatic aspects.

Authors:  Juan Zheng; Shih-Lung Woo; Xiang Hu; Rachel Botchlett; Lulu Chen; Yuqing Huo; Chaodong Wu
Journal:  Front Med       Date:  2015-02-12       Impact factor: 4.592

Review 5.  Hepatic fatty acid trafficking: multiple forks in the road.

Authors:  Douglas G Mashek
Journal:  Adv Nutr       Date:  2013-11-06       Impact factor: 8.701

Review 6.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

Review 7.  Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.

Authors:  Claudia Filozof; Barry J Goldstein; Richard N Williams; Arun Sanyal
Journal:  Drugs       Date:  2015-08       Impact factor: 9.546

8.  Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis.

Authors:  Pei Lin; Jianmei Lu; Yanfang Wang; Wen Gu; Jie Yu; Ronghua Zhao
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

9.  Serum TAG analysis differentiates between genetic and obesity-associated NAFLD.

Authors:  Douglas G Mashek; Andrew S Greenberg
Journal:  Diabetes       Date:  2014-01       Impact factor: 9.461

Review 10.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.

Authors:  Chris Estes; Homie Razavi; Rohit Loomba; Zobair Younossi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-12-01       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.